Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 7,646 matching trials from the live ClinicalTrials.gov search.

Filters: Jacksonville, Florida Clear all

Conditions: Hypercholesterolemia
Interventions: Lapaquistat acetate and atorvastatin, Atorvastatin; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 78
States / cities: Birmingham, Alabama • Northport, Alabama • Sierra Vista, Arizona + 75 more

Conditions: Colorectal Cancer
Interventions: Capecitabine, Irinotecan; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 17
States / cities: Birmingham, Alabama • Loma Linda, California • Norwich, Connecticut + 12 more

Conditions: Chronic Kidney Disease
Interventions: Verinurad, Allopurinol, Placebo for Verinurad, Placebo for Allopurinol; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 861 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 54
States / cities: Huntsville, Alabama • Bakersfield, California • Canyon Country, California + 45 more

Conditions: HER2-positive Breast Cancer
Interventions: tucatinib, placebo, T-DM1; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 321
States / cities: Mobile, Alabama • Gilbert, Arizona • Goodyear, Arizona + 180 more

Conditions: Intracranial Glioma
Interventions: Awake Anesthesia Protocol, Non-awake Anesthesia Protocol; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Breast Cancer
Interventions: Single nucleotide polymorphism (SNP), high performance liquid chromatography, measurements by DXA, questionnaire administration; Genetic · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 4
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 1 more

Conditions: Liver Transplant Disorder
Interventions: Liver Transplantation; Procedure
Lead sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS; Other
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Los Angeles, California • Jacksonville, Florida • Worcester, Massachusetts + 1 more

Conditions: Asthma
Interventions: Mometasone 220mcg BID, Tiotropium Respimat 5mcg QD, Placebo; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 12 Years and older
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 25
States / cities: Tucson, Arizona • San Francisco, California • Denver, Colorado + 13 more

Conditions: Severe Hypertriglyceridemia
Interventions: Olezarsen, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 63
States / cities: Birmingham, Alabama • Peoria, Arizona • Los Angeles, California + 51 more

Conditions: Dyslipidemia
Interventions: PRC-4016, Placebo, Statins; Drug
Lead sponsor: Pronova BioPharma; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 29
States / cities: Huntsville, Alabama • Muscle Shoals, Alabama • Beverly Hills, California + 24 more

Conditions: Migraine
Interventions: AXS-07 (MoSEIC meloxicam and rizatriptan), Placebo; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 41
States / cities: Birmingham, Alabama • Mobile, Alabama • Colton, California + 37 more

Conditions: Major Depressive Disorder
Interventions: SPD489 (Lisdexamfetamine dimesylate), Matching placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 33
States / cities: Imperial, California • Los Alamitos, California • Oceanside, California + 28 more

Conditions: Breast Cancer
Interventions: bevacizumab, fulvestrant; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 205
States / cities: Scottsdale, Arizona • Hollywood, Florida • Jacksonville, Florida + 127 more

Conditions: Non-small Cell Lung Cancer
Interventions: Pumitamig, Pembrolizumab, Carboplatin, Pemetrexed, Paclitaxel; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 1,580 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 54
States / cities: Birmingham, Alabama • Anchorage, Alaska • Concord, California + 45 more

Conditions: Cardiac Arrhythmia
Interventions: Arrhythmia Management System (AMS); Device
Lead sponsor: Zoll Medical Corporation; Industry
Eligibility: 21 Years and older
Enrollment: 585 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 20
States / cities: Bakersfield, California • Long Beach, California • Los Angeles, California + 15 more

Conditions: Opioid-induced Constipation
Interventions: Naldemedine, Placebo; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 99
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 96 more

Conditions: Type 2 Diabetes
Interventions: Medically tailored meals; Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 25 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Jacksonville, Florida

Conditions: Major Depressive Disorder
Interventions: PRAX-114, Placebo; Drug
Lead sponsor: Praxis Precision Medicines; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 30
States / cities: Phoenix, Arizona • Garden Grove, California • Lafayette, California + 27 more

Conditions: Squamous Cell Lung Cancer
Interventions: gemcitabine/carboplatin, gemcitabine/carboplatin plus Iniparib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 67
States / cities: Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 61 more

Conditions: Diabetes Mellitus
Interventions: To utilize the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) to help prolong the length of time people with diabetes maintain adherence to GLP-1 and dual GIP/GLP-1 agonists; Device
Lead sponsor: Abbott Diabetes Care; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Paradise Valley, Arizona • Jacksonville, Florida • Miami Gardens, Florida + 5 more

Conditions: Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Interventions: Psychotherapy, Questionnaire Administration; Behavioral · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Diabetic Foot Ulcers
Interventions: Epiflo, Moist Wound Therapy; Device · Other
Lead sponsor: Neogenix, LLC dba Ogenix; Industry
Eligibility: 20 Years to 90 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 14
States / cities: Phoenix, Arizona • Tucson, Arizona • Encinitas, California + 11 more

Conditions: Diabetes Mellitus, Type 2, Hypertension
Interventions: Placebo, BI 10773; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 825 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 35
States / cities: Huntsville, Alabama • Phoenix, Arizona • Lincoln, California + 29 more

Conditions: Venous Leg Ulcer, Venous Ulcer, Venous Stasis Ulcer, Venous Stasis, Wound Heal, Wounds, Venous Insufficiency of Leg, Non-healing Wound
Interventions: TR987 0.1% gel + Standard of Care, Standard of care; Drug · Other
Lead sponsor: TR Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 33
States / cities: Tucson, Arizona • Castro Valley, California • Fresno, California + 27 more

Search by objective public record fields.

Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in Subjects With Primary Hypercholesterolemia

Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer

A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Awake vs. Asleep Craniotomy for Non-eloquent Gliomas

Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast Cancer

Developing Prediction Models for Allograft Failure After Liver Transplantation

Steroids In Eosinophil Negative Asthma

A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia

Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia

Initiating Early Control of Migraine Pain and Associated Symptoms

SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder

Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

Mobile Cardiac Telemetry and Advanced Multi-Parameter Monitoring in Patients

Long Term Safety of Naldemedine

Effect of Medically-tailored Meal Delivery Service on Changes in Hemoglobin A1c (HbA1c) in Patients With Diabetes

A Clinical Trial of PRAX-114 in Participants With Major Depressive Disorder

Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)

Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring

Psychotherapy (Accelerated Resolution Therapy) for Cancer Related Trauma and Distress

Transdermal Continuous Oxygen Therapy for Diabetic Foot Ulcers

12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus

Tissue Repair Gel in Venous Leg Ulcers (US)